公开(公告)号：US20070264228A1

公开(公告)日：2007-11-15

申请号：US11548487

申请日：2006-10-11

申请人： Kevin Klucher ,  Pallavur Sivakumar ,  Wayne Kindsvogel ,  Katherine Henderson

发明人： Kevin Klucher ,  Pallavur Sivakumar ,  Wayne Kindsvogel ,  Katherine Henderson

IPC分类号： A61K45/00

CPC分类号： A61K47/60 ,  A61K38/20 ,  A61K38/21 ,  C07K14/54 ,  Y02A50/385 ,  Y02A50/393

摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

公开(公告)号：US20070259844A1

公开(公告)日：2007-11-08

申请号：US10561656

申请日：2004-06-21

申请人： Jong Kim

发明人： Jong Kim

IPC分类号： A61K31/573 ,  A61K38/21 ,  A61K31/7056 ,  A61K31/551 ,  A61K31/522

CPC分类号： A61K31/70 ,  A61K38/212 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/465 ,  A61K2300/00

摘要： Pharmaceutical compositions for and methods of preventing infection or treating an individual who has been identified as being infected with a Flavivirus, Pestivirus, picornovirus or coronavirus such as HCV, GB virus B, JEV, WNV, CSFV, BDV, BVDV, poliovirus, FMDV, or EMCV, comprising administering to the individual a therapeutically effective amount of one or more glucocorticoid receptor antagonist compounds, wherein said compound has steroidal structure are disclosed.

摘要翻译： 用于预防感染或治疗被鉴定为感染黄病毒，瘟病毒，小细小病毒或冠状病毒如HCV，GB病毒B，JEV，WNV，CSFV，BDV，BVDV，脊髓灰质炎病毒，FMDV的个体的药物组合物和方法， 或EMCV，包括向个体施用治疗有效量的一种或多种糖皮质激素受体拮抗剂化合物，其中所述化合物具有甾体结构。

公开(公告)号：US20070225307A1

公开(公告)日：2007-09-27

申请号：US11753462

申请日：2007-05-24

申请人： Lynne Bannen ,  Diva Chan ,  Jeff Chen ,  Lisa Dalrymple ,  Timothy Forsyth ,  Tai Huynh ,  Vasu Jammalamadaka ,  Richard Khoury ,  James Leahy ,  Morrison Mac ,  Grace Mann ,  Larry Mann ,  John Nuss ,  Jason Parks ,  Craig Takeuchi ,  Yong Wang ,  Wie Xu

发明人： Lynne Bannen ,  Diva Chan ,  Jeff Chen ,  Lisa Dalrymple ,  Timothy Forsyth ,  Tai Huynh ,  Vasu Jammalamadaka ,  Richard Khoury ,  James Leahy ,  Morrison Mac ,  Grace Mann ,  Larry Mann ,  John Nuss ,  Jason Parks ,  Craig Takeuchi ,  Yong Wang ,  Wie Xu

IPC分类号： A61K31/517 ,  A61K31/4709 ,  A61K31/4704 ,  C07D401/02 ,  C07D403/02 ,  C07D417/02

CPC分类号： C07D215/233 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  C07D215/22 ,  C07D215/36 ,  C07D215/38 ,  C07D215/46 ,  C07D239/88 ,  C07D239/94 ,  C07D295/15 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C12Q1/485 ,  G01N2500/04 ,  Y02A50/393

摘要： The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

摘要翻译： 本发明提供调节蛋白激酶酶活性以调节细胞活性如增殖，分化，程序性细胞死亡，迁移和化学侵蚀的化合物。 更具体地，本发明提供抑制，调节和/或调节与细胞活性变化相关的激酶受体，特别是c-Met，KDF，c-Kit，flt-3和flt-4信号转导途径的喹唑啉和喹啉 如上所述，含有这些化合物的组合物，及其用于治疗激酶依赖性疾病和病症的方法。 本发明还提供了制备上述化合物的方法和含有这些化合物的组合物。

公开(公告)号：US20070142292A1

公开(公告)日：2007-06-21

申请号：US11677796

申请日：2007-02-22

申请人： Atul Varadhachary ,  Peter Glynn ,  Karel Petrak ,  Jose Engelmayer

发明人： Atul Varadhachary ,  Peter Glynn ,  Karel Petrak ,  Jose Engelmayer

IPC分类号： A61K38/17 ,  C07K14/47 ,  C07H21/04 ,  C12P21/06

CPC分类号： A61K31/198 ,  A61K38/00 ,  C07K14/79 ,  Y02A50/393 ,  Y02A50/463

摘要： The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.

摘要翻译： 本发明涉及由一系列新的生物活性33聚体肽组成的组合物。

公开(公告)号：US20070099855A1

公开(公告)日：2007-05-03

申请号：US10559495

申请日：2004-06-07

申请人： Jindrich Cinatl

发明人： Jindrich Cinatl

IPC分类号： A61K31/704

CPC分类号： A61K45/06 ,  A61K31/04 ,  A61K31/704 ,  A61K31/7042 ,  A61K38/212 ,  Y02A50/393 ,  A61K2300/00

摘要： The invention provides methods for preventing, treating, managing or ameliorating viral infections, in particular, Severe Acute Respiratory Syndrome (SARS). More specifically, the invention provides methods for preventing, treating, managing or ameliorating a SARS-associated coronavirus or one or more symptoms thereof by administering Glycyrrhizin and/or derivatives thereof The invention also provides methods for preventing, treating, managing or ameliorating a SARS-associated coronavirus or one or more symptoms thereof by administering Glycyrrhizin and/or a derivative thereof in combination with a prophylactic or therapeutic agent other than Glycyrrhizin or a derivative thereof.

摘要翻译： 本发明提供了预防，治疗，治疗或改善病毒感染，特别是严重急性呼吸综合征（SARS）的方法。 更具体地，本发明提供了通过施用甘草甜素和/或其衍生物来预防，治疗，控制或改善与SARS相关的冠状病毒或其一种或多种症状的方法。本发明还提供了用于预防，治疗，控制或改善SARS- 通过与除甘草甜素或其衍生物以外的预防或治疗剂组合施用甘草甜素和/或其衍生物，与冠状病毒或其一种或多种症状相关。

公开(公告)号：US20070072181A1

公开(公告)日：2007-03-29

申请号：US10545864

申请日：2004-02-26

申请人： Lawrence Blatt

发明人： Lawrence Blatt

IPC分类号： C12Q1/70 ,  C12Q1/68

CPC分类号： A61K31/4412 ,  A61K38/212 ,  Y02A50/393 ,  A61K2300/00

摘要： The present invention provides methods for treating alphavirus infections; methods of treating hepatitis C virus (HCV) infections; methods of treating West Nile virus infection; methods of reducing liver fibrosis; methods of increasing liver function in an individual suffering from liver fibrosis; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from viral infection. The methods generally involve administering effective amounts of an interferon receptor agonist and pirfenidone in combination therapy.

摘要翻译： 本发明提供了治疗甲病毒感染的方法; 治疗丙型肝炎病毒（HCV）感染的方法; 治疗西尼罗病毒感染的方法; 减少肝纤维化的方法 增加肝纤维化患者肝功能的方法; 减少与HCV和肝硬化相关并发症发生率的方法; 以及在患有病毒感染的患者中减少病毒载量或减少病毒清除时间或减少临床结果的发病率或死亡率的方法。 所述方法通常涉及在组合疗法中施用有效量的干扰素受体激动剂和吡非尼酮。

公开(公告)号：US20070071721A1

公开(公告)日：2007-03-29

申请号：US11548479

申请日：2006-10-11

申请人： Kevin Klucher ,  Pallavur Sivakumar ,  Wayne Kindsvogel ,  Katherine Henderson

发明人： Kevin Klucher ,  Pallavur Sivakumar ,  Wayne Kindsvogel ,  Katherine Henderson

IPC分类号： A61K38/21

CPC分类号： A61K47/60 ,  A61K38/20 ,  A61K38/21 ,  C07K14/54 ,  Y02A50/385 ,  Y02A50/393

摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

公开(公告)号：US20070054937A1

公开(公告)日：2007-03-08

申请号：US11555418

申请日：2006-11-01

申请人： Masako NOZAKI

发明人： Masako NOZAKI

IPC分类号： A61K31/47

CPC分类号： A61K31/41 ,  A61K31/353 ,  Y02A50/393

摘要： A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid space by determining their ability to inhibit increased capillary permeability and white blood cell extravasation.

公开(公告)号：US20070015204A1

公开(公告)日：2007-01-18

申请号：US11531931

申请日：2006-09-14

申请人： Kevin Klucher ,  Pallavur Sivakumar ,  Wayne Kindsvogel ,  Katherine Henderson

发明人： Kevin Klucher ,  Pallavur Sivakumar ,  Wayne Kindsvogel ,  Katherine Henderson

IPC分类号： C12Q1/70 ,  C12Q1/68

CPC分类号： A61K47/60 ,  A61K38/20 ,  A61K38/21 ,  C07K14/54 ,  Y02A50/385 ,  Y02A50/393

摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

公开(公告)号：US20060142204A1

公开(公告)日：2006-06-29

申请号：US10534905

申请日：2003-10-09

申请人： Philippe Halfon ,  Chalom Sayada ,  Jean-Marc Feryn ,  Regis Perbost ,  Frederic Garzino ,  Michel Camplo ,  Jerome Courcambeck ,  Gerard Pepe

发明人： Philippe Halfon ,  Chalom Sayada ,  Jean-Marc Feryn ,  Regis Perbost ,  Frederic Garzino ,  Michel Camplo ,  Jerome Courcambeck ,  Gerard Pepe

IPC分类号： A61K38/05 ,  A61K38/04 ,  C07K5/06 ,  C07K5/04

CPC分类号： C07D207/16 ,  A61K38/00 ,  C07K5/06104 ,  C07K5/06191 ,  C07K5/0808 ,  C07K5/0819 ,  C07K5/0827 ,  C07K5/101 ,  C07K7/06 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02P20/55

摘要： The present invention relates to novel hepatitis C virus (“HCV”) protease inhibitors or other flavivirus protease inhibitors having the general structure (I) or (II), pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to treat hepatitis C and related disorders together with their use for their activity towards NS3 serine protease, intermediary compounds for the method of preparation of said compounds and screening methods. The invention specifically discloses novel chemical compounds as inhibitors of the HCV serine protease.

摘要翻译： 本发明涉及具有一般结构（I）或（II）的新型丙型肝炎病毒（“HCV”）蛋白酶抑制剂或其他黄病毒蛋白酶抑制剂，含有一种或多种这种抑制剂的药物组合物，制备这种抑制剂的方法， 这些化合物用于治疗丙型肝炎和相关疾病以及它们对NS3丝氨酸蛋白酶的活性的用途，用于制备所述化合物的方法的中间体化合物和筛选方法。 本发明特别公开了作为HCV丝氨酸蛋白酶抑制剂的新化合物。